KCA
Search
- Page Path
- HOME > Search
Original Article
- Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis
- Jwa Hoon Kim, Sook Ryun Park, Min-Hee Ryu, Baek-Yeol Ryoo, Kyu-pyo Kim, Beom Su Kim, Moon-Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Jihun Kim, Sun-Ju Byeon, Yoon-Koo Kang
- Cancer Res Treat. 2018;50(2):518-529. Published online May 24, 2017
- DOI: https://doi.org/10.4143/crt.2017.005
-
Abstract
PDF
PubReader
ePub - Purpose
The purpose of this study was to evaluate the efficacy and safety of induction chemotherapy with docetaxel, capecitabine, and cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic gastric cancer (GC).
Materials and Methods
Patients with LAGC or unresectable PAN metastatic GC received six induction chemotherapy cycles (60 mg/m2 docetaxel intravenously on day 1, 937.5 mg/m2 capecitabine orally twice daily on days 1-14, 60 mg/m2 cisplatin intravenously on day 1, and 7.5 mg/kg BEV intravenously on day 1 every 3 weeks), followed by conversion surgery. The primary endpoint was R0 resection rate.
Results
Thirty-one patients with invasion to adjacent organs but without PAN metastasis (n=14, LAGC group) or with PAN metastasis regardless of invasion (n=17, PAN group) were enrolled between July 2010 and December 2014. Twenty-seven patients (87.1%) completed six chemotherapy cycles. The most common grade ≥ 3 toxicities were neutropenia (71%), neutropenia with fever/infection (22.6%/3.2%), and stomatitis (16.1%). The clinical response and R0 resection rates were 64.3% (95% confidence interval [CI], 46.6 to 82.0) and 64.5% (LAGC group, 71.4%; PAN group, 58.8%), respectively. The pathological complete regression rate was 12.9%. After a median follow-up of 44.5 months (range, 39.4 to 49.7 months), the median progression-free survival and overall survival were 13.1 months (95% CI, 8.9 to 17.3) and 38.6 months (95% CI, 22.0 to 55.1), respectively.
Conclusion
Induction chemotherapy with DXP+BEV displayed antitumor activities with encouraging R0 resection rate and manageable toxicity profiles on patients with LAGC or PAN metastatic GC. -
Citations
Citations to this article as recorded by
- Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer
Liang Wang, Wei Li, Ya-Gang Liu, Cui Zhang, Wei-Na Gao, Li-Fei Gao, Wei long Zhong
Journal of Oncology.2022; 2022: 1. CrossRef - Neoadjuvant Bevacizumab Plus Docetaxel/Cisplatin/Capecitabine Chemotherapy in Locally Advanced Gastric Cancer Patients: A Pilot Study
Deguo Yu, Zhenfeng Wang, Tingbang He, Lijun Yang
Frontiers in Surgery.2022;[Epub] CrossRef - Research progress in targeted therapy and immunotherapy for gastric cancer
Xuewei Li, Jun Xu, Jun Xie, Wenhui Yang
Chinese Medical Journal.2022; 135(11): 1299. CrossRef - Novel Drug Delivery Method Targeting Para-Aortic Lymph Nodes by Retrograde Infusion of Paclitaxel into Pigs’ Thoracic Duct
Akira Saito, Natsuka Kimura, Yuji Kaneda, Hideyuki Ohzawa, Hideyo Miyato, Hironori Yamaguchi, Alan Kawarai Lefor, Ryozo Nagai, Naohiro Sata, Joji Kitayama, Kenichi Aizawa
Cancers.2022; 14(15): 3753. CrossRef - New therapeutic options opened by the molecular classification of gastric cancer
Mihaela Chivu-Economescu, Lilia Matei, Laura G Necula, Denisa L Dragu, Coralia Bleotu, Carmen C Diaconu
World Journal of Gastroenterology.2018; 24(18): 1942. CrossRef - Gastric cancer: Basic aspects
Henrique O. Duarte, Joana Gomes, José C. Machado, Celso A. Reis
Helicobacter.2018;[Epub] CrossRef
- Clinical Efficacy and Safety of Bevacizumab, Apatinib, and Recombinant Human Endothelial Inhibitor in the Treatment of Advanced Gastric Cancer
- 9,399 View
- 320 Download
- 11 Web of Science
- 6 Crossref
Case Report
- Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases
- Ji Seon Oh, Jae-Lyun Lee, Mi-Jung Kim, Min-Hee Ryu, Heung Moon Chang, Tae Won Kim, Se Jin Jang, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Yoon-Koo Kang
- Cancer Res Treat. 2006;38(3):178-183. Published online June 30, 2006
- DOI: https://doi.org/10.4143/crt.2006.38.3.178
-
Abstract
PDFPubReaderePub
Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the
c-kit gene in two patients, and wild-typec-kit andPDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST.-
Citations
Citations to this article as recorded by- Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
Dong-Hoe Koo, Min-Hee Ryu, Kyoung-Mee Kim, Han-Kwang Yang, Akira Sawaki, Seiichi Hirota, Jie Zheng, Bo Zhang, Chin-Yuan Tzen, Chun-Nan Yeh, Toshirou Nishida, Lin Shen, Li-Tzong Chen, Yoon-Koo Kang
Cancer Research and Treatment.2016; 48(4): 1155. CrossRef - Correlation between Computed Tomography and Pathological Findings of Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate
Ki Choon Sim, Beom Jin Park, Na Yeon Han, Deuk Jae Sung, Min Ju Kim, Sung Bum Cho, Hyun Kwon Ha, Hyoung Rae Kim
Journal of the Korean Society of Radiology.2014; 71(5): 239. CrossRef - Diagnosis and Treatment of Gastrointestinal Stromal Tumor
Yoon-Koo Kang, Dong Hoe Koo
Korean Journal of Medicine.2013; 85(4): 341. CrossRef - Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Hye Jin Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Cancer Research and Treatment.2012; 44(2): 85. CrossRef - Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee
Journal of the Korean Society of Coloproctology.2011; 27(3): 147. CrossRef - Clinical Practice Guideline for Accurate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang, Kyoung-Mee Kim, Taesung Sohn, Dongil Choi, Hye Jin Kang, Min-Hee Ryu, Woo Ho Kim, Han-Kwang Yang
Journal of Korean Medical Science.2010; 25(11): 1543. CrossRef - Clinical Practice Guideline for Adequate Diagnosis and Effective Treatment of Gastrointestinal Stromal Tumor in Korea
Yoon-Koo Kang
Journal of the Korean Medical Association.2007; 50(9): 830. CrossRef
- Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor
- 11,356 View
- 86 Download
- 7 Crossref
Original Articles
- Efficacy and Safety Study of Docetaxel as Salvage Chemotherapy in Metastatic Gastric Cancer Failing Fluoropyrimidine and Platinum Combination Chemotherapy
- Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Jung Shin Lee, Yoon-Koo Kang
- Cancer Res Treat. 2005;37(4):201-207. Published online August 31, 2005
- DOI: https://doi.org/10.4143/crt.2005.37.4.201
-
Abstract
PDFPubReaderePub
Purpose Fluoropyrimidine (F) and platinum (P) combination chemotherapy has been widely used for the first line treatment of advanced gastric cancer (AGC). Docetaxel (D) has shown promising activity in this disease. The present study retrospectively investigated the efficacy of D monotherapy as salvage chemotherapy for AGC that is failing F and P combination chemotherapy.
Materials and Methods A total of 34 patients, fitting the eligibility criteria, were included in this study. D was administered at a dose of 75 mg/m2 IV every 3 weeks, with dexamethasone prophylaxis. Twenty-nine patients had measurable lesions. The median treatment-free interval was 38.5 days, and 91.2% of patients had progressed within 4 months of withdrawal of the first line chemotherapy.
Results A total of 133 cycles of D were administered, with a median of 3.5 (1~8) cycles. From an intention-to-treat analysis, 6 patients achieved partial responses (PR), with a response rate of 20.7% (95% CI, 6.0~35.4). The duration of objective PRs in these six were 2.3+, 2.5+, 2.9, 3.0+, 6.2 and 6.8 months, respectively. Six patients showed a stable disease, but 15 showed progression. The median time to progression was 4.2 months (95% CI, 2.8~5.5), with a median overall survival since the start of D monotherapy of 8.4 months (95% CI, 5.5~11.3). Grade 3/4 neutropenia and febrile neutropenia occurred in 12.9% of patients and 3.1% of cycles. The incidence of grade 3 or worse non-hematological toxicities were as follows; peripheral sensory neuropathy 9.7%, asthenia 3.2% and allergic reaction 2.7%.
Conclusion Docetaxel, 75 mg/m2, is active in AGC as second-line chemotherapy after failure of prior exposure to the F and P combination chemotherapy, with a favorable toxicity profile.
-
Citations
Citations to this article as recorded by- Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
Nao Tagawa, Erika Sugiyama, Masataka Tajima, Yasutsuna Sasaki, Seigo Nakamura, Hiromi Okuyama, Hisanori Shimizu, Vilasinee Hirunpanich Sato, Tadanori Sasaki, Hitoshi Sato
Cancer Chemotherapy and Pharmacology.2017; 80(4): 841. CrossRef - Efficacy and Safety of Trastuzumab-based Therapy in Combination with Different Chemotherapeutic Regimens in Advanced Esophagogastric Cancer – a Single Cancer-center Experience
Georg-Martin Haag, Leonidas Apostolidis, Dirk Jaeger
Tumori Journal.2014; 100(3): 237. CrossRef - Phase I Dose-Escalation Study of Intravenous Aflibercept in Combination with Docetaxel in Patients with Advanced Solid Tumors
Nicolas Isambert, Gilles Freyer, Sylvie Zanetta, Benoît You, Pierre Fumoleau, Claire Falandry, Laure Favier, Sylvie Assadourian, Karen Soussan-Lazard, Samira Ziti-Ljajic, Veronique Trillet-Lenoir
Clinical Cancer Research.2012; 18(6): 1743. CrossRef - A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy
Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Tae-Won Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim, Minsun Kim, Young Joo Chun, Jung Shin Lee, Yoon-Koo Kang
Cancer Chemotherapy and Pharmacology.2008; 61(4): 631. CrossRef
- Comparison of adverse events following injection of original or generic docetaxel for the treatment of breast cancer
- 9,943 View
- 54 Download
- 4 Crossref
- Clinicopathological Analysis of Borrmann Type IV Gastric Cancer
- Jeong Hwan Yook, Sung Tae Oh, Byung Sik Kim
- Cancer Res Treat. 2005;37(2):87-91. Published online April 30, 2005
- DOI: https://doi.org/10.4143/crt.2005.37.2.87
-
Abstract
PDFPubReaderePub
Purpose Borrmann type IV gastric cancer is often diagnosed only at an advanced stage, resulting in a prognosis poor. We performed a retrospective study of the clinical characteristics of Borrmann type IV gastric cancer and the prognostic factors affecting the survival rate in such patients.
Materials and Methods Of 4,063 patients with all gastric cancers, 370 (9%) with Borrmann type IV gastric cancer were analyzed.
Results The clinical characteristics of these patients included a higher incidence rate in young females, and higher rates of serosa exposure, metastasis to lymph nodes and early peritoneal dissemination. Of patients presenting with peritoneal seeding, those resected had a higher survival rate than those that were not. A univariate analysis showed that the prognostic factors affecting the survival rate following a curative resection were the location, occupied area and depth of the primary tumor, as well as the presence of lymph node metastasis and the tumor stage. A multivariate analysis indicated that the tumor location and stage were significant independent prognostic factors after a curative resection for Borrmann type IV gastric cancer.
Conclusion In conclusion, the early diagnosis and treatment of patients with Borrmann type IV gastric cancer are essential for the better survival of these patients. Even in patients with advanced tumors, a noncurative palliative resection may improve the prognosis.
-
Citations
Citations to this article as recorded by- Borrmann Type IV Gastric Cancer: Computed Tomography Features and Corresponding Pathological Findings
Changfeng Ji, Yi Ma, Zhong Zheng, Song Liu, Zhengyang Zhou
Journal of Computer Assisted Tomography.2024; 48(2): 200. CrossRef - Clinicopathological and prognostic features of Borrmann type IV gastric cancer versus other Borrmann types: A unique role of signet ring cell carcinoma
Chengcai Liang, Yao Liang, Biyi Ou, Lei Yuan, Shuqiang Yuan
Saudi Journal of Gastroenterology.2023; 29(4): 240. CrossRef - PN3b as an independent risk factor for poor prognosis and peritoneal recurrence in Borrmann type IV gastric cancer: A retrospective cohort study
Yiran Chen, Yanyan Chen, Liping Wen, Laizhen Tou, Haiyong Wang, Lisong Teng
Frontiers in Surgery.2022;[Epub] CrossRef - Comparative Outcomes of Laparoscopic Gastrectomy and Open Gastrectomy for Scirrhous Gastric Cancer: A Multicenter Retrospective Cohort Study
Yusuke Fujita, Tatsuto Nishigori, Yoshio Kadokawa, Atsushi Itami, Masato Kondo, Hisahiro Hosogi, Seiichiro Kanaya, Hironori Kawada, Hiroaki Hata, Michihiro Yamamoto, Yousuke Kinjo, Eiji Tanaka, Dai Manaka, Seiji Satoh, Hiroshi Okabe, Shigeru Tsunoda, Masa
Annals of Surgery Open.2021; 2(2): e063. CrossRef - Are Borrmann’s Types of Advanced Gastric Cancer Distinct Clinicopathological and Molecular Entities? A Western Study
Cristina Díaz del Arco, Luis Ortega Medina, Lourdes Estrada Muñoz, Elena Molina Roldán, M. Ángeles Cerón Nieto, Soledad García Gómez de las Heras, M. Jesús Fernández Aceñero
Cancers.2021; 13(12): 3081. CrossRef - Borrmann Type IV Gastric Cancer: Focus on the Role of Gastrectomy
Chengcai Liang, Guoming Chen, Baiwei Zhao, Haibo Qiu, Wei Li, Xiaowei Sun, Zhiwei Zhou, Yingbo Chen
Journal of Gastrointestinal Surgery.2020; 24(5): 1026. CrossRef - Subtotal gastrectomy combined with chemotherapy: An effective therapy for patients with circumscribed Borrmann type IV gastric cancer
Hai-Bo Huang, Zi-Ming Gao, An-Qi Sun, Wei-Tian Liang, Kai Li
World Journal of Gastrointestinal Oncology.2020; 12(11): 1325. CrossRef - Role of Cancer-Associated Fibroblast in Gastric Cancer Progression and Resistance to Treatments
In-Hye Ham, Dagyeong Lee, Hoon Hur
Journal of Oncology.2019; 2019: 1. CrossRef - Endoscopic ultrasound‑guided fine‑needle aspiration biopsy for diagnosis of gastric linitis plastica with negative malignant endoscopy biopsies
Yingjian Ye, Shiyun Tan
Oncology Letters.2018;[Epub] CrossRef - Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer
Makiko Yasumoto, Etsuko Sakamoto, Sachiko Ogasawara, Taro Isobe, Junya Kizaki, Akiko Sumi, Hironori Kusano, Jun Akiba, Takuji Torimura, Yoshito Akagi, Hiraku Itadani, Tsutomu Kobayashi, Shinichi Hasako, Masafumi Kumazaki, Shinji Mizuarai, Shinji Oie, Hiro
Cancer Medicine.2017; 6(1): 235. CrossRef - Endoscopic ultrasound-guided cutting of holes and deep biopsy for diagnosis of gastric infiltrative tumors and gastrointestinal submucosal tumors using a novel vertical diathermic loop
Yu-Mei Liu, Xiu-Jiang Yang
World Journal of Gastroenterology.2017; 23(15): 2795. CrossRef - Clinicopathologic characteristics and prognosis of Borrmann type IV gastric cancer: a meta-analysis
Yifan Luo, Peng Gao, Yongxi Song, Jingxu Sun, Xuanzhang Huang, Junhua Zhao, Bin Ma, Yuan Li, Zhenning Wang
World Journal of Surgical Oncology.2016;[Epub] CrossRef - Borrmann type IV gastric cancer should be classified as pT4b disease
Jin-yu Huang, Zhen-ning Wang, Chun-yang Lu, Zhi-feng Miao, Zhi Zhu, Yong-xi Song, Hui-mian Xu, Ying-ying Xu
Journal of Surgical Research.2016; 203(2): 258. CrossRef - Limited significance of curative surgery in Borrmann type IV gastric cancer
Eun Young Kim, Han Mo Yoo, Kyo Young Song, Cho Hyun Park
Medical Oncology.2016;[Epub] CrossRef - An update on gastric cancer
Syed A. Ahmad, Brent T. Xia, Christina E. Bailey, Daniel E. Abbott, Beth A. Helmink, Meghan C. Daly, Ramya Thota, Cameron Schlegal, Leah K. Winer, S. Ameen Ahmad, Ali H. Al Humaidi, Alexander A Parikh
Current Problems in Surgery.2016; 53(10): 449. CrossRef - CA125 is a potential biomarker to predict surgically incurable gastric and cardia cancer
Taobo Luo, Wenhu Chen, Lifang Wang, Hongguang Zhao
Medicine.2016; 95(51): e5297. CrossRef - Undiagnosed Borrmann type IV gastric cancer despite repeated endoscopic biopsies and PET-CT examination: A case report
Fang-Qing Zhu, Hong-Jin Chu, Zhao-Hua Gong, Feng-Cai Du, Jian Chen, Li-Xin Jiang
Oncology Letters.2016; 12(2): 1485. CrossRef - Variable Endoscopic Findings and Clinicopathological Characteristics of Borrmann Type 4 Advanced Gastric Cancer
Ji Young Chang, Ki-Nam Shim, Chung Hyun Tae, A Reum Choe, Chang Mo Moon, Seong-Eun Kim, Hye-Kyung Jung, Sung-Ae Jung
The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2015; 15(3): 166. CrossRef - Survival Benefit of Palliative Gastrectomy in Gastric Cancer Patients with Peritoneal Metastasis
Masanori Tokunaga, Masanori Terashima, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Hirofumi Yasui, Narikazu Boku
World Journal of Surgery.2012; 36(11): 2637. CrossRef - Risk Stratification for Serosal Invasion Using Preoperative Predictors in Patients with Advanced Gastric Cancer
Sung-Sil Park, Jae-Seok Min, Kyu-Jae Lee, Sung-Ho Jin, Sunhoo Park, Ho-Yoon Bang, Hwang-Jong Yu, Jong-Inn Lee
Journal of Gastric Cancer.2012; 12(3): 149. CrossRef - An Insufficient Preoperative Diagnosis of Borrmann Type 4 Gastric Cancer in Spite of EMR
Jae Bong Ahn, Tae Kyung Ha, Hang Rak Lee, Sung Joon Kwon
Journal of Gastric Cancer.2011; 11(1): 59. CrossRef - Gastric carcinoma: when is palliative gastrectomy justified?
Hubert Scheidbach, Hans Lippert, Frank Meyer
Oncology Reviews.2010; 4(2): 127. CrossRef - Prognostic Factors in Gastric Cancer Patients with Peritoneal Carcinomatosis
Hyun Il Kim, Tae Kyung Ha, Sung Joon Kwon
Journal of Gastric Cancer.2010; 10(3): 126. CrossRef - Prognosis of pN3 Stage Gastric Cancer
Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, Hye Ryun Kim, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
Cancer Research and Treatment.2009; 41(2): 73. CrossRef - Borrmann Type IV: An Independent Prognostic Factor for Survival in Gastric Cancer
Ji Yeong An, Tae Ho Kang, Min Gew Choi, Jae Hyung Noh, Tae Sung Sohn, Sung Kim
Journal of Gastrointestinal Surgery.2008; 12(8): 1364. CrossRef - Prognostic Factors for Advanced Gastric Cancer: Stage-stratified Analysis of Patients who Underwent Curative Resection
Joong-Min Park, Woo-Sang Ryu, Jong-Han Kim, Sung-Soo Park, Seung-Joo Kim, Chong-Suk Kim, Young-Jae Mok
Cancer Research and Treatment.2006; 38(1): 13. CrossRef
- Borrmann Type IV Gastric Cancer: Computed Tomography Features and Corresponding Pathological Findings
- 11,278 View
- 104 Download
- 26 Crossref
- Therapeutic Effect of the Intraperitoneal Cisplatin Installation (IPCI) in Advanced Gastric Carcinoma with Serosa Invasion Retrospective study
- Haeng Su Kim, Jin Ho Kwak, Yong Ho Kim, Chang Hwan Lee, Jung Hwan Yook, Seung Tae Oh, Byung Sik Kim, Keun Chun Park
- J Korean Cancer Assoc. 2000;32(6):1015-1021.
-
Abstract
PDF
- PURPOSE
We performed retrospective study to evaluate the preventive effect of intraperitoneal cisplatin installation (IPCI) on peritoneal recurrence after curative resection of advanced gastric cancer.
MATERIALS AND METHODS
The effect of IPCI was evaluated in 297 advanced gastric carcinoma patients from January 1993 to December 1996. In IPCI group, 100 mg/body of cisplatin in one liter of saline was installed in peritoneal cavity before wound closure in operating room and drained out 2 hours later. Postoperative adjuvant chemotherapy with combination of 5-FU and cisplain was performed. 155 cases were treated by IPCI. Median follow-up period was 26 months.
RESULTS
Out of 139 (46.8%) recurred cases, peritoneal, local and distant recurrences developed in 65 (37.8%) cases, 66 (38.4%) cases and 41 (23.8%) cases respectively. In univariated analysis for survival and recurrence, IPCI, T stage and N stage were significant prognostic factors. As regards to peritoneal recurrence, IPCI and T stage were significant factors. In multivariated survival analysis, as regards to recurrence, IPCI, T stage and N stage were significant prognostic factors. As regards to peritoneal recurrence, IPCI was the only significant independent prognostic factor.
CONCLUSION
We concluded that IPCI can effectively prevent peritoneal recurrence and overall recurrence and it shows marginal survival benefit in advanced gastric cancer patients with serosa invasion.
- 2,785 View
- 18 Download
- The Significance of Serum CA 19 - 9 Level in Gastric Adenocarcinoma
- Yong Jin Kim, Byung Sik Kim, Jeong Hwan Yook, Sung Tae Oh, Byung Sun Suh, Wan Soo Kim, Yong Ho Kim, Kun Chun Park
- J Korean Cancer Assoc. 2000;32(1):38-43.
-
Abstract
PDF
- PURPOSE
This study was designed to investigate the significance of preoperative serum CA 19-9 level as a prognostic factor and postoperative serum CA 19-9 level as an indicator for recurrence in gastric adenocarcinoma patients.
MATERIALS AND METHODS
328 patients, who received curative resection of stomach for gastric cancer from 1989 to 1996 and followed up successfully, were analyzed retrospec- tively. Median follow-up period was 24 months (range: 11-38 months). The cut off level of serum CA 19-9 was 37 U/ml. The relationships between preoperative serum CA 19-9 status and prognostic parameters, recurrence and survival rate were analyzed. Multivariate analysis using Cox proportional hazards regression analysis was performed to evaluate as an independent prognostic factor. The relationship between postoperative serum CA 19-9 level and recurrence was investigated.
RESULTS
Out of 328 cases, 29 cases (8.8%) showed elevated preoperative serum CA 19-9 level. The preoperative serum CA 19-9 level was correlated with the degree of depth of invasion and the status of lymph node metastasis (p<0.05). Patients with positive pre- operative serum CA 19-9 status showed higher incidence of recurrence (p<0.05) and poorer survival rate (p=0.00003) than patients with negative status. Preoperative serum CA 19-9 status (risk ratio: 3.4464, p=0.0039) revealed as an independent prognostic factor in multivariate analysis. Postoperative serum CA 19-9 status revealed as a useful predictor for recurrence in patients with positive preoperative serum CA 19-9 status.
CONCLUSION
Preoperative serum CA 19-9 determination in patients with gastric cancer was valuable for predicting tumor progression and prognosis. Preoperative serum CA 19-9 status may be helpful to predict recurrence earlier than other diagnostic tools, especially in the patients with positive preoperative serum CA 19-9 status.
- 3,070 View
- 17 Download
- Diagnostic Value of Tumor Markers in Stomach Cancer
- Jeong Hwan Yook, Byung Sik Kim, Yong Ho Kim, Byung Sun Suh, Wan Soo Kim, Sung Tae Oh, Kun Chun Park
- J Korean Cancer Assoc. 1999;31(6):1094-1100.
-
Abstract
PDF
- PURPOSE
CEA, CA19-9, and CA72-4 are the most commonly used tumor markers in stomach cancer. This clinical study was performed to evaluate the diagnostic value of these tumor markers in stomach cancer patients.
MATERIALS AND METHODS
A retrospective analysis of 170 stomach cancer patients who had undergone curative gastrectomy between January 1991 and December 1996 at the Department of Surgery was performed. The preoperative and postoperative serum levels of these tumor markers were measured in 170 patients.
RESULTS
The preoperative positive cases were 28 cases (16%) in CEA, 15 (9%) in CA19-9, and 24 (14%) in CA72-4. The postoperative positive cases among 48 recurrences were 21 cases (44%) in CEA, 10 (21%) in CA19-9, and 10 (21%) in CA72-4. The combination of CEA with CA19-9 or CA72-4 had higher positivity rate (58%) than single tumor marker. The highest positivity rate was found in CEA at recurrences of anastomotic site, in CA19-9 at recurrences of lymph node, in CA72-4 at peritoneal seeding and distant metastasis. In multivariate analysis, these tumor markers were not independent prognostic factors.
CONCLUSION
CEA, CA19-9, and CA72-4 have proved unhelpful in initial diagnosis of stomach cancer because of their low positivity rate. And the combination of 3 tumor markers was the useful method for raising positivity rate in diagnosis of recurrences.
- 4,549 View
- 60 Download
- In Vitro Chemosensitivity Test for the Evaluation of Efficiency of Hyperthermia in Gastrointestinal Cancer Cell Lines
- Jeong Hwan Yook, Byeong Yul Ahn, Geum Hee Koo, Hun Seo, Choon Sik Jeong, Sung Tae Oh, Byung Sik Kim, Kun Chun Park, Jin Cheon Kim
- J Korean Cancer Assoc. 1999;31(5):931-938.
-
Abstract
PDF
- PURPOSE
This study was designed to establish the experimental background of intra- peritoneal hyperthermo-chemotherapy in gastrointestinal cancer.
MATERIALS AND METHODS
We established stomach cancer cell lines; KATO-III, MKN45, AMC1 and colon cancer cell lines; AMC5, AMC6, CloneA, CCL188, C106, KM-12C. We performed chemosensitivity test by using MTT assay and calculated ICso of each chemotherapeutic agent. We confirmed antitumor effect of hyperthermia at 40C and 43C and antitumor synergistic effect with each chemotherapeutic agent at 40C and 43C.
RESULTS
The ICso was calculated in 7 (78%) of 9 cell lines for 5-FU, 6 (67%) for MMC, 5 (56%) for ADM, 1 (11%) for CDDP and VP-16. Antitumor effect of hyperthermia at 40C was not found, but, that at 43C was found except KATO-III and AMC6. In stomach cancer cell lines, antitumor synergistic effect of hyperthermia with anticancer drugs at 43C was found in VP-16 for MKN45 and KATO-III and in all of 5 drugs for AMC1. In colon cancer cell lines, this effect at 43C was found in all of 5 drugs for CCL188, in S-FU, CDDP, ADM for AMC5, in 5-FU, MMC, ADM, VP-16 for CloneA, KM-12C, and in 5-FU, CDDP, MMC, ADM for C106.
CONCLUSION
Hyperthermia itself had antitumor effect at 43C. Hyperthermo-chemotherapy had antitumor synergistic effect, especially at 43C.
- 2,571 View
- 21 Download
- Matrix Metalloproteinases and Their Inhibitors in Gastric Carcinoma
- Byung Sik Kim, Yutaka Yonemura, Hideto Fujita, Naomi Nojima, Taiichi Kawamuta, Sachio Fushida, Takashi Fujimura, Itsuo Miyazaki, Kouichi Miwa, Hiroshi Itoh, Raul Falla, Yoshio Endo, Takuma Saski, Hiroshi Yamamoto
- J Korean Cancer Assoc. 1999;31(5):912-920.
- 2,401 View
- 14 Download
- Primary Signet Ring Cell Carcinoma of the Colon and Rectum
- Hee Chul Kim, Chang Nam Kim, Choon Sik Jeong, Chang Sik Yu, Byung Sik Kim, Hun Kyung Lee, Jin Cheon Kim
- J Korean Cancer Assoc. 1998;30(3):521-526.
-
Abstract
PDF
- PURPOSE
Signet ring cell carcinoma is a rare type of adenocarcinoma in the colon and rectum. We evaluated the differences of clinical features between colorectal signet ring cell carcinoma and ordinary adenocarcinoma.
MATERIALS AND METHODS
The clincopathologic data of 13 cases with primary colorectal signet ring cell carcinoma were reviewed. The primary colorectal signet ring cell carcinoma was diagnosed when following criteria were met: 1) the tumor was primary; 2) histologic material was adequate; 3) signet ring cells represented more than 50% of the cancer.
RESULTS
Patients ranged in age from 20 to 68 (median, 45) years; 7 were male, and 6 were female. Three tumors were located in the proximal colon, 3 in the distal colon, and 7 in the rectum. There was no case that had family history. Most cases (77%) were stage III, one was stage II, and two were stage IV with peritoneal seeding. There were 9 cases that showed local recurrence or distant metastases during follow-up periods 6 cases with peritoneal seeding, 3 with bone metastases, 2 with brain metastases and 1 with pelvic recurrence (two cases had either bone and brain metastasis, and one case had bone and peritoneal seeding). Prognosis was extremely poor, and overall two years survival rate was 25%. CONCLUSION: Early onset, mode of metastasis and poor prognosis may imply the different biologic behavior of signet ring cell carcinoma, compared with ordinary adenocarcinoma. To improve outcome, early diagnosis and radical operation should be stressed.
- 4,691 View
- 97 Download
- Changes of serum carcinoembryonic antigen in patients with colorectal cancer
- Jin Cheon Kim, Dae Yong Hwang, Byung Sik Kim, Young Il Min, Myung Hae Lee, Kun Choon Park
- J Korean Cancer Assoc. 1992;24(6):880-884.
- 2,774 View
- 14 Download
- Clinical evaluation of the Port-A-Cath implantation
- Jin Kyung Lee, Sung Gyu Lee, Byung Sik Kim, Tae Won Kwon, Pyung Chul Min
- J Korean Cancer Assoc. 1992;24(3):450-455.
- 2,040 View
- 14 Download
- Applicability of DMH-induced colorectal tumor model in respect to carcinogenesis
- Jin Cheon Kim, Gyeong Yeop Gong, Kyoo Yeon Park, Byung Sik Kim, Kun Choon Park, In Chul Lee
- J Korean Cancer Assoc. 1992;24(2):239-248.
- 2,315 View
- 13 Download
- Correlation of c-erbB-2 protein overexpression in human breast carcinoma with nodal status, tumor size, stage, age and survival
- Byung Sik Kim, Dong Young Noh, Kak Jin Choe, Kuhn Kuk Lee, Seong Hoe Park, Yong Il Kim, Joo Bae Park
- J Korean Cancer Assoc. 1991;23(1):20-28.
- 2,218 View
- 13 Download
- The Effect of laminin and Type 4 Collagen on the Adhesion and Invasion of Human Gastrocytes and Gastric Cancer Cells In Vitro
- Byung Sik Kim, Jin Cheon Kim, Seon Ae Roh, Kun Choon Park, Kuk Jin Choe
- J Korean Cancer Assoc. 1995;27(3):360-374.
-
Abstract
PDF
- Extracellular matrix is important in the metastasis of tumor, and basement membrane acts not only as tissue barrier but also as adhesive substrate for tumor cell invasion. Laminin and type IV collagen are major components of basement membrane and important in tumor invasion. Adhesion and invasion studies about metastasis of the tumor have been performed mainly in colon cancer or breast cancer but rare in gastric cancer. The purpose of this study was to investigate the difference in the ability of adhesion to the basement membrane and their biological activity between the normal gastrocyte and gastric cancer cells. Then, The role of basement membrane in tumor invasion was assessed by the evaluation of the invasion of gastric cancer cells of different histological differentiation. Gastrocytes;, ere isolated from the surgically resected specimen by treating with collagenase and deoxyribonuclease. Normal gastrocytes were maintained viable up to 24 hours after isolation. The isolated cells were confirmed as gastric epithelial cells by indirect immuno- fluorescence staining for cytokeratin. Although the adhesion of normal gastrocyte was lower than that of gastric cancer cells, gastrocyte was bound to laminin and type IV collagen. The substrates were shown to play an important role for the differentiation and regeneration of gastrocytes also. In the invasion assay using transwell cell culture chamber coated with matrigel, laminin and type IV collagen enhanced tumor cell invasion (p<0.05). However, there was no difference according to histological differentiation. In conclusion, it can be suggested that laminin and type IV collagen must be important for the biologicaf activity of normal gastrocyte and metastasis of gastric cancer celL Type IV collagen enhances the invasion of gastric cancer cell more than laminin does.
- 2,942 View
- 33 Download
First
Prev
